Discounted Cash Flow Rating

Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

SCYNEXIS, Inc. (SCYX)

Pharmaceutical Preparations

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

1 EVERTRUST PLAZA, 13TH FLOOR
JERSEY CITY, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/02/2014

Market Cap

66,110,872

Shares Outstanding

37,210,000

Weighted SO

37,207,799

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

BFRI --.--%

GHSI --.--%

SHPH --.--%

AKAN --.--%

CPHI --.--%

EGRX --.--%

PAHC --.--%

SSIC --.--%

PCRX --.--%

Beta

1.5150

Last Div

0.0000

Range

1.35-3.87

Chg

0.0199

Avg Vol

180717

Mkt Cap

66110872

Exch

NASDAQ

Country

US

Phone

201 884 5485

DCF Diff

1.4744

DCF

-0.0044

Div Yield

0.0000

P/S

6.8388

EV Multiple

-1.0676

P/FV

1.4053

Div Yield %

0.0000

P/E

-2.3987

PEG

-0.0123

Payout

0.0000

Current Ratio

3.7482

Quick Ratio

3.7482

Cash Ratio

1.0452

DSO

745.4050

DIO

0.0000

Op Cycle

745.4050

DPO

128.5380

CCC

616.8669

Gross Margin

-0.5715

Op Margin

-5.3696

Pretax Margin

-3.5917

Net Margin

-3.6609

Eff Tax Rate

-0.0150

ROA

-0.3283

ROE

-0.4727

ROCE

-0.6286

NI/EBT

1.0193

EBT/EBIT

0.6689

EBIT/Rev

-5.3696

Debt Ratio

0.1442

D/E

0.2573

LT Debt/Cap

0.0380

Total Debt/Cap

0.2047

Int Coverage

-62.0909

CF/Debt

-0.6551

Equity Multi

1.7847

Rec Turnover

0.4897

Pay Turnover

2.8396

Inv Turnover

0.0000

FA Turnover

4.3292

Asset Turnover

0.0897

OCF/Share

-0.2099

FCF/Share

-0.2099

Cash/Share

1.5134

OCF/Sales

-1.0534

FCF/OCF

1.0000

CF Coverage

-0.6551

ST Coverage

-0.7740

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.4053

P/B

1.4053

P/S

6.8388

P/E

-2.3987

P/FCF

-6.4923

P/OCF

-8.3365

P/CF

-8.3365

PEG

-0.0123

P/S

6.8388

EV Multiple

-1.0676

P/FV

1.4053

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 13, 17:17 SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Revenue Product Segmentation